Pro-Dex, Inc. (PDEX) Market Cap
Pro-Dex, Inc. has a market capitalization of $174.2M.
Financials based on reported quarter end 2025-12-31
Price: $53.40
▲ 0.80 (1.52%)
Market Cap: 174.19M
NASDAQ · time unavailable
CEO: Richard Lee Van Kirk Jr.
Sector: Healthcare
Industry: Medical - Instruments & Supplies
IPO Date: 1986-08-07
Website: https://www.pro-dex.com
Pro-Dex, Inc. (PDEX) - Company Information
Market Cap: 174.19M · Sector: Healthcare
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
Analyst Sentiment
Based on 1 ratings
Consensus Price Target
No data available
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"PDEX reported annual revenue of $18.66M with a net income of $2.19M, reflecting an EPS of $0.67. The company maintains total assets of $62.26M against liabilities of $20.63M, yielding a robust equity position of $41.63M. During the last year, PDEX's stock price saw negligible movement at -0.02%, despite a strong 6-month gain of 47.42% and a year-to-date performance increase of 32.53%. The operating cash flow is healthy at $3.57M, and the company has not paid any dividends. With zero capital expenditure, cash generation remains stable. The company's total debt is manageable at $3.88M, affirming a favorable leverage scenario. Overall, PDEX shows sound profitability but needs to improve shareholder returns and stock price performance to achieve a more balanced profile."
Revenue Growth
Revenue of $18.66M indicates moderate growth potential.
Profitability
Net income of $2.19M reflects positive profitability.
Cash Flow Quality
Strong operating cash flow with no capital expenditures.
Leverage & Balance Sheet
Solid balance sheet with manageable debt and high equity.
Shareholder Returns
Limited shareholder returns with no dividends and minimal price appreciation.
Analyst Sentiment & Valuation
Mixed sentiment with recent stock performance; valuation requires further analysis.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
So what: Q1 FY2015 showed relatively flat top-line growth ($2.6M, +2% YoY) driven by a rebound in the largest customer (+$400k), but profitability deteriorated sharply. Gross margin fell to 32% from 37% (down 5 pts) as management pointed to lower-margin product mix versus repairs, plus higher accruals for anticipated losses on fixed-price development contracts and under-absorbed manufacturing costs. The analyst-style pressure in the Q&A focused less on accounting and more on timing: management reiterated products are in final testing and should move into manufacturing/shipment within the fiscal year, while acknowledging that testing is lengthy. On capital return, a shareholder asked about buyback scope: management confirmed ~41k shares repurchased so far and that the $750k board-approved authorization is not yet being fully pursued. Overall tone is constructive (customer frames, engineering services launch), but the hard numbers show execution/profitability headwinds remain immediate.
Growth Catalysts
- Resumption of product shipments to the largest medical customer (after suspension March–November 2013) and expected follow-on frame contracts
- Engineering Services Division launch (engineering consulting and placement services) expected to add revenue and create business-development synergies
Business Development
- Largest medical company customer: resumption of shipments in December 2013 and receipt of follow-on frame contracts
- Engineering Services Division target: placement/contract engineer services and potential consulting from in-house staff (prospects via shared engineering/contact base, incl. GM Marvin Gidney and VP of Engineering)
Financial Highlights
- Net sales: $2.6M, +2% YoY ($2.5M prior year). Underlying drivers: +$400k sales to largest customer; -$183k repair revenue from former largest medical device customer; -$151k sales to another customer
- Gross profit: $828k, down $117k (-12%) YoY; gross margin % declined to 32% from 37% (down 5 percentage points)
- Gross margin headwinds: product mix shift (less high-margin repairs, more lower-margin product sales), higher accruals for anticipated losses on fixed-price product development services, and under-absorbed manufacturing costs from reduced volumes
- Partially offset: lower inventory and warranty charges due to downward revision in estimated per-unit repair costs
- Operating expenses: +10% to $1.0M YoY (primarily business development expense increases and project-related legal costs)
- Operating results: loss from continuing operations -$181k vs income +$18k prior year; net loss -$170k (-$0.04/share) vs net income $212k (+$0.06/share) prior year (prior-year net income included $167k gain on sale of Carson City facility in discontinued ops)
Capital Funding
- Share repurchase activity disclosed in Q&A: ~41,000 shares repurchased so far (Q&A)
- Board-approved repurchase plan referenced: $750,000 total approved a year ago, but management stated current repurchase plan is not for the entire amount and details were not disclosed
Strategy & Ops
- Product development projects: management characterized them as in final phase of testing; still expects manufacturing and product shipment phase to begin within fiscal 2015 (timeline remained contingent on a 'lengthy' testing phase)
- New Engineering Services Division launched: aims to use internal engineering talent and shared contact base to sell a menu of services (placement of engineers on contract basis and potential consulting)
Market Outlook
- Management maintained outlook: product shipments expected within the current fiscal year (Q&A)
- Next earnings timing: expects to report fiscal year 2015 Q2 and first half results in February (closing remarks)
Risks & Headwinds
- Operational profitability pressure from lower-margin mix: repairs (higher gross margin) vs product sales (lower gross margin) following resumption of product shipments
- Fixed-price development services risk: increased accruals for anticipated losses on certain contracts
- Manufacturing inefficiency risk: under-absorbed manufacturing costs tied to reduced volumes
- Product development testing remains a pacing constraint: final testing phase described as 'lengthy' with ongoing execution risk
- Tax/NOL risk mitigated in Q&A: management stated no issues with tax implications on net operating losses
Sentiment: MIXED
Note: This summary was synthesized by AI from the PDEX Q1 2015 (ended September 30, 2014) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.